WARREN, N.J., Oct. 19, 2015 (GLOBE NEWSWIRE) -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, recently presented on the Company's advancements in oral peptide drug delivery utilizing its PharmFilm technology at The Boulder Peptide Symposium, Boulder, CO, and Partnerships in Drug Delivery Conference 2015, Boston, MA. Nozer Mehta Ph.D., MonoSol Rx Vice President of Biologics, was the presenter at both conferences.
The oral podium presentations, entitled "Advantages of Mucoadhesive Buccal Films for the Delivery of Peptides" and "Advantages of PharmFilm® Buccal Delivery Technology for Small Molecules and Peptides" highlighted the company's study of buccal peptide delivery with Exenatide and Octreotide. These chronic therapy drugs, like the majority of peptides, are traditionally delivered by injection.
Dr. Mehta commented, "MonoSol Rx's PharmFilm already boasts a number of technical advantages as a drug delivery technology. As we actively expand our development pathway to include peptide drugs to our pipeline, the findings from the early preclinical studies support the successful application of this technology for oral peptide delivery."
Read more: http://globenewswire.com/news-release/2015/10/19/777383/10152876/en/MonoSol-Rx-Leadership-Presents-Data-Supporting-PharmFilm-Technology-Effective-for-Oral-Peptide-Delivery.html